Precision BioSciences Inc
DTIL
Company Profile
Business description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
102
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.20 | 10.40 | -0.11% |
| CAC 40 | 7,743.93 | 34.12 | 0.44% |
| DAX 40 | 24,046.21 | 106.66 | -0.44% |
| Dow JONES (US) | 45,565.23 | 147.16 | 0.32% |
| FTSE 100 | 9,255.50 | 10.30 | -0.11% |
| HKSE | 25,032.08 | 169.68 | -0.67% |
| NASDAQ | 21,590.14 | 45.87 | 0.21% |
| Nikkei 225 | 42,790.60 | 270.33 | 0.64% |
| NZX 50 Index | 12,920.19 | 58.35 | 0.45% |
| S&P 500 | 6,481.40 | 15.46 | 0.24% |
| S&P/ASX 200 | 8,969.10 | 1.40 | -0.02% |
| SSE Composite Index | 3,803.08 | 2.73 | 0.07% |